Engflag

Lincomycin 20%

Quick links to important sections

Lincomycin 20%

Lincomycin 20%_EN

Method of action: Bacteriostatic

Treatment option: Viral Infection, Infection, Infection,Bacterial, Colitis, Colitis,Pseudomembranous, Prevent Infections, Sepsis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lincomycin 20%

What is Lincomycin 20%? The Foundational Identity of the Medicine

Lincomycin 20% is a medicinal product defined by its active component, Lincomycin, and its formulation as a sterile aqueous solution for injection. It belongs to the lincosamide antibiotic class, making it an effective antimicrobial agent used to restrict the growth of susceptible bacteria within the body. This product is a single-active-ingredient solution intended for use in medicine.

Quick Facts

Property Description
Active Ingredient Lincomycin
Form Sterile Aqueous Solution for Injection
Pharmacological Class Lincosamide Antibiotic
Common Use Targeting Susceptible Bacterial Infections
Origin Semisynthetic

The Classification and Origin of Lincomycin

Lincomycin is an antimicrobial agent that holds the distinction of being the original compound of the lincosamide antibiotic class. This pharmacological classification is crucial, as the agent is derived from the bacterium Streptomyces lincolnensis, making it a semisynthetic substance. This characteristic origin and class are clinically recognized for their unique spectrum of activity against certain anaerobic organisms. The compound's structural similarity to Clindamycin, its semisynthetic derivative, further solidifies its position within this specific family of anti-infective agents.

Composition and Form: Understanding the 20% Injectable Solution

Lincomycin 20% is formulated as a sterile aqueous solution for injection, containing the active substance Lincomycin (typically as the hydrochloride salt) at a 20% concentration. This preparation dictates that the medicine is intended for parenteral delivery, which means it must be administered by injection rather than through the digestive system. The 20% concentration is an identity feature that signifies the product’s high potency. The injectable liquid form is often favored in situations requiring rapid systemic distribution and reliable absorption of the active ingredient.

Lincomycin's General Therapeutic Purpose

The overall purpose of Lincomycin is to function as a bacteriostatic agent to help the body address infections caused by specific, susceptible bacterial populations. By operating at the cellular level, the drug suppresses the ability of the invading microorganisms to grow and multiply. This action of restricting the bacterial population's growth rate is the fundamental therapeutic benefit of Lincomycin, effectively weakening the infection and supporting the host's natural defenses in resolving the bacterial issue.

What side effects are possible with Lincomycin 20%?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible adverse reactions of Lincomycin based on frequency and the body system affected. The medicine’s safety profile is primarily characterized by effects on the gastrointestinal system and skin, as defined in governmental prescribing information.

Frequency and System-Organ Classes

The most common adverse reactions listed include diarrhea, nausea, and vomiting, alongside localized reactions at the injection site, such as pain or induration. Uncommon effects typically involve skin reactions like pruritus (itching) and urticaria (hives), as well as headache.

Side effects are officially classified across several System-Organ Classes, including Gastrointestinal disorders, Skin and subcutaneous tissue disorders, Blood and lymphatic system disorders, and Hepatobiliary disorders.

Serious Adverse Reactions and Safety Constraints

The most serious risk documented in official labeling is the potential for Pseudomembranous Colitis (Clostridioides difficile-associated diarrhea), which is a rare but significant event that may occur during or up to several weeks following the completion of therapy. Other rare but severe adverse reactions include severe changes in blood cell counts (such as agranulocytosis), severe skin conditions (Stevens-Johnson syndrome), and anaphylactic reactions.

Safety constraints require that Lincomycin not be administered to individuals with a documented history of hypersensitivity to either Lincomycin or Clindamycin. Furthermore, official labeling notes that patients with pre-existing conditions like renal or hepatic impairment, or a history of gastrointestinal disease, may require specific monitoring due to altered clearance or increased risk of colitis.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations of Lincomycin overdose and the emergency actions mandated by regulatory authorities. This information is derived exclusively from government-approved prescribing information.

Documented Overdose Manifestations

Primary Regulatory Concern Specific Manifestation
Neuromuscular System Toxicity The potential for neuromuscular blockade, which may lead to respiratory compromise.
Gastrointestinal System Exaggerated gastrointestinal effects, including severe diarrhea and pseudomembranous colitis.
Cardiovascular Risk Hypotension and cardio-respiratory arrest, particularly when administered intravenously faster than the official recommended rate.

Required Emergency Actions and Management

Official regulatory guidance requires that immediate medical attention must be sought for any suspected overdose. Due to the potential for severe, life-threatening outcomes, prompt contact with emergency services is mandated.

Treatment is strictly symptomatic and supportive. Regulatory documentation explicitly states that no specific antidote is known for Lincomycin overdose. Furthermore, procedures like peritoneal dialysis are documented as ineffective for removing Lincomycin from the bloodstream.

Population-Specific Note: Caution and monitoring are required for patients with severe hepatic or renal impairment, as these conditions can prolong the drug's half-life and increase the risk of accumulation in an overdose scenario.

Therapeutic Uses of Lincomycin 20%

What Lincomycin 20% Treats: Main Uses and Benefits

Lincomycin 20% is applied in addressing conditions marked by increased physiological stress, such as serious bacterial infections, caused by susceptible pathogens.

Therapeutic Scope and Key Benefits

Lincomycin is considered relevant for managing serious systemic conditions, including septicemia (blood poisoning) and severe lower respiratory infections like bacterial pneumonia. It is also commonly used across conditions presenting with acute episodes that localize in structural tissues, such as osteomyelitis, septic arthritis, and deep skin and soft tissue infections like cellulitis and abscesses. This therapeutic action is used to help with managing acute systemic symptoms, which may assist with easing the overall symptom load like persistent high fever and supporting general well-being during symptomatic phases.

For patients with a confirmed allergy to penicillin-class antibiotics, Lincomycin is considered relevant as a therapeutic alternative for susceptible infections. The drug is commonly used to help with managing serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. Its use assists with maintaining functional stability by providing essential anti-infective support when symptoms interfere with routine activities.

QuickFact Block

Quick Fact: Supportive Management for Key Symptom Clusters
Supports the management of symptoms related to inflammatory or irritative states, such as localized pain and swelling in deep skin and joint infections.
Contributes to easing the overall symptom load, such as high fever and systemic distress, linked to septicemia and severe pneumonia.
Is relevant when supportive symptom management is appropriate, particularly when alternative anti-infective agents are not suitable.

Regulatory References

  1. FDA-approved labeling for Lincomycin Injection

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lincomycin 20%

This section summarizes official regulatory information regarding patient eligibility for Lincomycin 20%.

Populations for Whom Use is Prohibited or Restricted

Classification Population/Condition
Contraindicated Individuals with a prior history of hypersensitivity (severe allergic reaction) to lincomycin or clindamycin (a chemically related drug).
Contraindicated Patients with meningitis (inflammation of the meninges) are generally excluded from use due to inadequate drug levels in the cerebrospinal fluid.
Not Recommended Use is not recommended for nonbacterial infections (e.g., most viral infections) and must be reserved for serious infections in patients where less toxic alternatives (like penicillins) are inappropriate or contraindicated.
Not Established Infants and children under 1 month of age.

Special Considerations and Caution

Lincomycin 20% must be used with caution and requires special monitoring for certain groups:

  • Patients with severe renal impairment or abnormal hepatic function may require a dose adjustment.
  • Individuals with a history of gastrointestinal disease, particularly colitis.
  • Older adult patients should be closely monitored for changes in bowel frequency.
  • If the injectable form contains benzyl alcohol as a preservative, its use requires caution in premature infants due to the risk of serious adverse events.

Official Eligibility Profile: Lincomycin 20% is primarily reserved for treating serious bacterial infections caused by susceptible organisms in patients who are allergic to penicillins or when penicillin use is clinically inappropriate. Regulatory documents strictly define non-eligible groups, focusing on hypersensitivity and disease-specific limitations like meningitis, emphasizing caution for patients with organ impairment or a history of colitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory documentation for Lincomycin defines its interaction profile primarily through pharmacodynamic effects and physicochemical interferences with the oral formulation. No specific information on enzyme-mediated (CYP) or drug transporter interactions is listed in the official prescribing documents.

Interacting Substance/Class Official Interaction Pattern Administration Restriction/Rule
Neuromuscular Blocking Agents (NMBAs) Documented to enhance the action of NMBAs (e.g., rocuronium, pancuronium), potentially resulting in prolonged neuromuscular blockade due to pharmacodynamic synergism. Officially listed as an interaction where co-administration requires caution due to the risk of enhanced effect.
Macrolide Antibiotics An antagonistic effect, particularly with Erythromycin, is officially noted in regulatory sources, which may lead to a reduction in antimicrobial efficacy. Combination is restricted due to the documented risk of therapeutic antagonism.
Kaolin Co-administration of the oral form results in a significant reduction of gastrointestinal absorption, lowering Lincomycin plasma concentrations. Oral doses must be administered at least 2 hours apart from Kaolin to preserve adequate drug exposure.
Food The ingestion of food with the oral formulation is officially documented to reduce the overall extent of absorption. This absorption change applies only to the oral product form and is noted in the labeling.

Official Interaction Structure

The product’s official interaction structure is centered on specific constraints and observed regulatory outcomes. Co-administration with agents that facilitate neuromuscular blockade is officially documented due to the risk of effect enhancement, a pharmacodynamic concern. The combination with macrolides, such as Erythromycin, carries a formal restriction based on documented therapeutic antagonism. Furthermore, an explicit timing rule is established in the labeling, mandating that the oral form of Lincomycin and Kaolin be administered at least two hours apart to counteract the documented reduction in absorption. The oral product's absorption profile is also officially noted to be reduced by food.

Mechanism of Action

How Lincomycin 20% Works

Molecular Targeting of the 50S Ribosome

Lincomycin engages a mechanism that selectively targets the bacterial translational machinery, specifically the 50S ribosomal subunit. By binding directly to the 23S ribosomal RNA component near the peptidyl transferase center, the drug acts as an inhibitor to physically block the enzyme responsible for building proteins.

Inhibiting Protein Synthesis and Replication

This molecular blockade prevents the essential process of peptide chain elongation and seals the peptide exit tunnel, leading to a halt in the creation of proteins required for bacterial survival and replication. This pathway interference results in a bacteriostatic effect, meaning the drug stops the infectious microbial population from growing and multiplying, which results in the reduction of the infectious microbial load.

️ Understanding Mechanistic Limitations

The drug's effectiveness is constrained by two biological defense mechanisms, primarily ribosomal methylation of the 23S rRNA (the MLSB phenotype), which reduces Lincomycin's binding affinity. Separately, active efflux pumps can expel the drug from the cell, both of which are microbial strategies that functionally bypass the inhibitory mechanism.

Dosage and Administration Information

Instruction Map: How to use Lincomycin Injection

This section details the usage parameters for Lincomycin Injection.

Administration Scope

Instruction Entity Description
Route of administration The medicine is administered via Intramuscular (IM) injection or by Intravenous (IV) Infusion. Specialized Subconjunctival injection is also documented for specific ocular use.
Dosing schedule (Adults) IM (Serious Infection): 600 mg every 24 hours. IV (Severe Infection): 600 mg to 1 gram every 8 to 12 hours. The maximum recommended dose is up to 8 grams per day in divided doses.
Preparation requirements IV Administration: The sterile solution must be diluted prior to infusion with a compatible solution, such as 0.9% Sodium Chloride, to a final concentration not exceeding 10 mg/mL.
Age-group administration rules Pediatric (over 1 month old): Dosing is determined by weight, ranging from 10 mg/kg to 20 mg/kg/day, divided by the appropriate interval.

Instruction Classifications (High-Level)

Classification Entity Description
Administration method type Parenteral (Injectable: Intramuscular, Intravenous).
Frequency pattern Divided use (e.g., every 8, 12, or 24 hours) based on the severity of the condition.
Use-context constraints Organ Function Adjustment: Dose must be reduced to 25% to 30% for patients with severe renal impairment. Infusion Rate Restriction: Infusion must not exceed 1 gram per hour.

Resulting Procedural Structure

The administration process is defined by the parenteral route and precise dosage calculation. This protocol includes specific preparation and timing constraints for intravenous use:

  • If administering intravenously (IV), dilute the required dose to ensure the final concentration is 10 mg/mL or less.
  • Administer the solution via deep IM injection or slow IV infusion.
  • Do not administer the IV solution as an undiluted bolus (rapid push), and ensure the IV infusion time is at least one hour per gram of Lincomycin.
  • Adjust the dose if severe renal impairment is present.

Recent Clinical Evidence

Lincomycin 20%: Overview of Studies and Research Evidence

Evidence Profile for Serious Systemic Infections

Research examined Lincomycin in the context of serious systemic infections, such as septicemia and severe bacterial pneumonia, which are conditions involving periods of heightened symptoms and physiological strain. The initial regulatory evidence examined how the agent performed in the context of these infections. Studies typically included adult populations where the infection was observed in those susceptible to specific bacterial strains. Researchers primarily conducted Comparative Randomized Controlled Trials (RCTs) to assess the acute response, measuring Clinical Cure Rates and Bacteriological Eradication of the target organism, alongside the monitoring of acute systemic markers like high fever.

The findings describe patterns observed in the studies related to measured changes in acute systemic markers. This body of evidence is broadly categorized as Moderate in consistency, reflecting the level of consistency in study findings.

Evidence Profile for Bone and Joint Infections

Lincomycin was studied for its application in infections localized in structural tissues, such as osteomyelitis and septic arthritis. The evidence landscape primarily consists of Observational Cohort Studies, smaller Non-Comparative Trials, and Retrospective Case Series. Research explored outcomes related to functional imbalance, such as mobility and joint function, and studies monitored the frequency of infection recurrence. Variability was observed across various studies, often reflecting the complexity of the infections and reliance on concurrent surgical procedures. The evidence quality varies across studies, and the broad consistency is generally classified as Low to Moderate.

Evidence Profile for Skin, Soft Tissue Infections, and Use as an Alternative

Lincomycin was evaluated in studies addressing acute deep skin and soft tissue infections. Specific research was observed in some studies to determine its application in a distinct patient group: those with a confirmed allergy to penicillin-class antibiotics. The outcomes monitored included the Therapeutic Success Rate and the time required for outcomes linked to inflammatory or irritative states to resolve. The evidence contributes to the broader evidence landscape with a Moderate level of certainty.

Areas of Uncertainty and Research Gaps

Overall, the research highlights what is known — and what is still uncertain — about this agent. A significant limitation is that many pivotal studies are characterized by their older data sets and often have modest sample sizes. Comparative evidence is lacking for many modern therapeutic scenarios. The available follow-up durations were limited for many indications, meaning long-term outcomes lack robust data.

Key Studies & References Assessing the Therapeutic Effectiveness and Tolerability of Lincomycin Injectables in Skin and Soft Tissue Infections and Surgical Site Infections

How should Lincomycin 20% be stored and disposed of?

How to Store and Dispose of Lincomycin 20%

The storage of Lincomycin 20% sterile aqueous solution is strictly defined by regulatory requirements to ensure potency and sterility. The product must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and it must not freeze. Storage should be in a dry place, protected from light, and always kept in the original container.

Stability and Handling

Condition Requirement
Child Safety Keep out of reach of children (mandatory caution).
Stability After Opening Diluted solutions are typically stable for 24 hours at room temperature; multi-dose vials must be discarded within 21 days of first entry.

Disposal

Unused or expired Lincomycin 20% must be disposed of according to local regulations. Follow instructions for pharmaceutical waste, such as utilizing drug take-back programs, to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Lincomycin 20% found in:

A-Z Index: